SCLP Scancell Holdings plc

LSE · GB · Healthcare · Biotechnology · scancell.co.uk

9.400GBp-1.05%Mkt Cap: 138.62M $P/E: —Today

Scancell Holdings plc, a clinical stage biopharmaceutical company, discovers and develops of immunotherapies for the treatment of cancer in the United Kingdom. Its product candidates include SCIB1/iSCIB1+ that is in Phas…

Industry Peers

Biotechnology

Screen all

VRTX

Vertex Pharmaceuticals Incorporated - Common Stock

$127.85BUSDP/E 29.4

MRNA

Moderna, Inc. - Common Stock

$75.86BUSD

REGN

Regeneron Pharmaceuticals, Inc. - Common Stock

$75.69BUSDP/E 18.2

ARGX

argenx SE - American Depositary Shares

Revolution Medicines, Inc. - Common Stock

BeOne Medicines Ltd. - American Depositary Shares

$40.51BUSDP/E 63.9

RPRX

Royalty Pharma plc - Class A Ordinary Shares

$33.03BUSDP/E 30.7

ALNY

Alnylam Pharmaceuticals, Inc. - Common Stock

$29.40BUSDP/E 38.3

ROIV

Roivant Sciences Ltd. - Common Shares

$25.80BUSD

BNTX

BioNTech SE - American Depositary Shares

$24.34BUSD

INSM

Insmed Incorporated - Common Stock

$24.27BUSD

INCY

Incyte Corporation - Common Stock

Genmab A/S - American Depositary Shares

$21.69BUSDP/E 27.4

JAZZ

Jazz Pharmaceuticals plc - Ordinary Shares

$15.30BUSDP/E 16.1

ASND

Ascendis Pharma A/S - Ordinary Share

$14.99BUSDP/E 17.8

EXEL

Exelixis, Inc. - Common Stock

$14.47BUSDP/E 18.4

SMMT

Summit Therapeutics Inc. - Common Stock

$13.37BUSD

Key Statistics

Company

Market Cap138.62M USD

Enterprise Value115.43M USD

Revenue (TTM)5.12M USD

Gross Profit4.86M USD

Net Income (TTM)-13.34M USD

Revenue/Share0.0050 GBp

Last Price9.400 GBp

Fiscal Year EndApr 2025

MR QuarterOct 2025

Employees60

CountryGB

SectorHealthcare

IndustryBiotechnology

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)-8.80

PEG—

EV/EBITDA-8.19

EV/Revenue22.54

P/S27.36

P/B-11.88

EPS (TTM)-0.01

EPS (Forward)-0.01

52W Range

9.1002% of range27.00

52W High27.00 GBp

52W Low9.100 GBp

Profitability

Gross Margin94.95%

Oper. Margin-283.34%

EBITDA Margin-275.17%

Profit Margin-260.50%

ROE320.00%

ROA-53.15%

Growth

Revenue Growth—

Earnings Growth—

Cash Flow & Leverage

Operating CF-6.96M USD

CapEx (TTM)1.67M USD

FCF Margin-363.38%

FCF Yield-13.42%

Net Debt8.27M USD

Net Debt/EBITDA-0.59

Balance Sheet

Debt/Equity-4.24

Current Ratio0.56

Quick Ratio0.56

Book Value/Sh-0.0080 GBp

Cash/Share0.0080 GBp

Dividends

Fwd Div Rate—

Trail. Div Rate0.00 GBp

Div. Yield—

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div Date—

Pay Date—

Splits

Last Split10:1

Split DateJul 26, 2011

Analyst Consensus

Rating—

Target (Mean)25.50 GBp

Upside (mean)+171.3%

Target Range19.00 GBp – 32.00 GBp

19.00+171.3% to mean32.00

# Analysts2

Ownership

Shares Out.1.36B

Float648.32M

Insiders3.13%

Institutions38.03%

Technical

SMA 509.696 (-3.1%)

SMA 20013.59 (-30.8%)

Beta0.69

S&P 52W Chg14.58%

Avg Vol (30d)2.20M

Avg Vol (10d)1.19M

Technical Indicators

RSI (14)37.3

MACD-0.2458

MACD Signal-0.2780

MACD Hist.+0.0322

BB Upper10.15 GBp

BB Middle9.720 GBp

BB Lower9.287 GBp

BB Width8.92%

ATR (14)0.2748 GBp

Vol Ratio (20d)0.99x